Natriumkromoglikat Abece (Sodium Cromoglicate)

Sodium cromoglicate blocks calcium entry into mast cells, which prevents the cells from releasing histamine, leukotrienes and other inflammatory mediators. By inhibiting this degranulation process, the drug reduces the allergic cascade on the ocular surface, leading to relief of itching, redness and swelling.

The dosing regimen for Natriumkromoglikat Abece is determined by the prescribing clinician based on the severity of the allergic eye condition, patient age and response to therapy. The prescriber will specify the number of drops, frequency and duration appropriate for each individual case.

Safety data for sodium cromoglicate eye drops during pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against any unknown risks and discuss the decision with the patient. Use only if clearly indicated and prescribed by a qualified professional.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Unlike antihistamine eye drops that block histamine receptors, sodium cromoglicate stabilises mast cells, preventing the release of multiple inflammatory mediators. This broader mechanism can be advantageous in chronic or severe allergic eye disease, while antihistamines may provide faster relief of itching but do not address underlying mast‑cell activation.

Store the eye‑drop solution at room temperature, ideally below 25 °C, in its original packaging. Protect it from direct sunlight, moisture and extreme temperature fluctuations. Keep the container tightly closed when not in use and discard any product that appears discoloured or contaminated.

The product is applied as an ophthalmic solution. The patient should wash hands, tilt the head back, pull down the lower eyelid, and instil the prescribed number of drops into the conjunctival sac. Close the eyes gently for a few seconds and avoid blinking excessively to allow proper absorption.

Serious adverse events, although rare, include severe allergic reactions such as angioedema or anaphylaxis, ocular infections, corneal ulceration and sudden vision loss. Any of these symptoms require immediate medical evaluation and discontinuation of the product.

Patients with a known hypersensitivity to sodium cromoglicate or any excipients in the formulation should avoid using the product. It is also contraindicated in individuals who have experienced severe ocular reactions to mast‑cell stabilisers and in those for whom the prescriber determines the risk outweighs the benefit.